Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Medtronic ( (MDT) ) has provided an update.
Medtronic announced a leadership change in its Cardiovascular Portfolio, with Sean Salmon departing and Skip Kiil assuming the role of EVP and President, effective May 21, 2025. Additionally, Medtronic plans to separate its Diabetes business into a standalone public company. The company reported strong financial results for Q4 and FY25, with significant increases in revenue, operating profit, and earnings per share. Medtronic also announced a dividend increase, marking its 48th consecutive year of dividend growth, and highlighted advancements in its medical technologies, including FDA approvals and successful product launches.
The most recent analyst rating on (MDT) stock is a Hold with a $87.00 price target. To see the full list of analyst forecasts on Medtronic stock, see the MDT Stock Forecast page.
Spark’s Take on MDT Stock
According to Spark, TipRanks’ AI Analyst, MDT is a Outperform.
Medtronic’s strong financial performance and positive earnings call, highlighting consistent revenue and EPS growth, are significant strengths. However, technical indicators suggest caution due to potential overbought conditions. While the valuation appears high compared to industry norms, the attractive dividend yield offsets some concerns. The strategic growth focus and innovative pipeline enhance the company’s long-term prospects.
To see Spark’s full report on MDT stock, click here.
More about Medtronic
Medtronic plc is a global leader in healthcare technology, focusing on key franchises such as Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation.
Average Trading Volume: 7,438,502
Technical Sentiment Signal: Buy
Current Market Cap: $111.5B
See more insights into MDT stock on TipRanks’ Stock Analysis page.